ArticleFrontiers in medicine2025
Investigation of the pharmacological mechanisms of Denglao Qingguan decoction in inhibiting viral pneumonia through network pharmacology and
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Respiratory viral infection poses a serious threat to human health, underscoring the need for effective agents to prevent and treat these conditions. Objective: This study aimed to investigate Denglao Qingguan decoction (DLQGD), a traditional formula used in the management of respiratory infections, and to elucidate its efficacy and mechanisms against viral pneumonia. Methods: Network pharmacology was employed to investigate the potential mechanism of DLQGD against viral pneumonia. The components of DLQGD were analyzed by High-Performance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry (HPLC-Q-TOF MS). The antiviral effects of DLQGD against respiratory syncytial virus (RSV), influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were determined by cytopathic effect or MTT assays. The inhibitory effects of DLQGD on RSV or SARS-CoV-2-induced inflammatory response were determined by reverse transcriptase-quantitative PCR. Results: A total of 66 active ingredients were identified in DLQGD. Network pharmacology showed that DLQGD could regulate a total of 122 targets involved in viral pneumonia. The 50% inhibitory concentration (IC Conclusion: Collectively, these findings indicate that DLQGD exhibits antiviral and anti-inflammatory activities, suggesting that it could be developed into a therapeutic constituent for respiratory viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.